The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 438, 10.1056/NEJMoa1709866 Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Lee, 2018, ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow, 25, 625, 10.1016/j.bbmt.2018.12.758 Hay, 2018, Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy, Br J Haematol, 183, 362, 10.1111/bjh.15644 Neelapu, 2019, Managing the toxicities of CAR T-cell therapy, Hematol Oncol, 37, 48, 10.1002/hon.2595 Rhodes, 1987, Symptom distress–the concept: past and present, Semin Oncol Nurs, 3, 242, 10.1016/S0749-2081(87)80014-1 Cleeland, 2007, Symptom burden: multiple symptoms and their impact as patient-reported outcomes, J Natl Cancer Inst Monogr, 16, 10.1093/jncimonographs/lgm005 Mooney, 2017, Improving cancer care through the patient experience: how to use patient-reported outcomes in clinical practice, Am Soc Clin Oncol Educ Book, 37, 695, 10.1200/EDBK_175418 Cella, 2008, Improving health-related quality of life in non-small-cell lung cancer with current treatment options, Clin Lung Cancer, 9, 206, 10.3816/CLC.2008.n.030 Parse, 1985 Cleeland, 2011, Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial, J Clin Oncol, 29, 994, 10.1200/JCO.2010.29.8315 Fagundes, 2015, Symptom recovery after thoracic surgery: measuring patient-reported outcomes with the MD Anderson Symptom Inventory, J Thorac Cardiovasc Surg, 150, 613, 10.1016/j.jtcvs.2015.05.057 Shi, 2016, Patient-reported symptom interference as a measure of postsurgery functional recovery in lung cancer, J Pain Symptom Manage, 52, 822, 10.1016/j.jpainsymman.2016.07.005 Gunn, 2013, High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study, Head Neck, 35, 1490, 10.1002/hed.23181 Wang, 2008, Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation, Cancer, 113, 2102, 10.1002/cncr.23820 Wang, 2010, Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy, Brain Behav Immun, 24, 968, 10.1016/j.bbi.2010.03.009 Wang, 2012, Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy, Brain Behav Immun, 26, 699, 10.1016/j.bbi.2011.12.007 Hanna, 2015, The symptom burden of treatment-naive patients with head and neck cancer, Cancer, 121, 766, 10.1002/cncr.29097 Rosenthal, 2014, Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module, Cancer, 120, 1975, 10.1002/cncr.28672 Kamal, 2019, Fatigue following radiation therapy in nasopharyngeal cancer survivors: a dosimetric analysis incorporating patient report and observer rating, Radiother Oncol, 133, 35, 10.1016/j.radonc.2018.12.023 Kamal, 2018, Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors, Radiother Oncol, 126, 75, 10.1016/j.radonc.2017.10.037 Sailors, 2013, Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer, Gynecol Oncol, 130, 323, 10.1016/j.ygyno.2013.05.009 Armstrong, 2010, Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module, J Neurosurg Spine, 12, 421, 10.3171/2009.10.SPINE0943 Armstrong, 2006, Validation of the MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT), J Neurooncol, 80, 27, 10.1007/s11060-006-9135-z Gning, 2009, Development and initial validation of the thyroid cancer module of the M.D. Anderson Symptom Inventory, Oncology, 76, 59, 10.1159/000178809 Jones, 2014, The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group, Clin Genitourin Cancer, 12, 41, 10.1016/j.clgc.2013.07.003 Mendoza, 2011, Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the MD Anderson Symptom Inventory, Oncologist, 16, 217, 10.1634/theoncologist.2010-0193 Mendoza, 2013, The validity and utility of the M.D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group, Clin Breast Cancer, 13, 325, 10.1016/j.clbc.2013.02.014 Rosenthal, 2007, Measuring head and neck cancer symptom burden: the development and validation of the M.D. Anderson symptom inventory, head and neck module, Head Neck, 29, 923, 10.1002/hed.20602 Wang, 2010, Validation and application of a module of the M.D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI), Cancer, 116, 2053, 10.1002/cncr.24920 Williams, 2018, Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM), Qual Life Res, 27, 3229, 10.1007/s11136-018-1982-5